<DOC>
	<DOCNO>NCT01720147</DOCNO>
	<brief_summary>Fanconi anemia ( FA ) autosomal recessive disease characterize progressive bone marrow failure ( BMF ) , congenital abnormality predisposition malignancy .</brief_summary>
	<brief_title>Quercetin Children With Fanconi Anemia ; Pilot Study</brief_title>
	<detailed_description>Current therapy child Fanconi anemia ( FA ) bone marrow failure , i.e . androgens bone marrow transplantation , associate significant morbidity mortality . This pilot study aim assess feasibility , toxicity pharmacokinetics oral Quercetin therapy patient FA . This first step towards clinical study efficacy Quercetin therapy delay progression BMF FA . Additional correlative study include assessment impact Quercetin reduction Reactive Oxygen Species ( ROS ) , maintenance improvement hematopoietic stem cell ( HSC ) reserve , improvement hematopoiesis ( i.e . peripheral count ) insulin sensitivity/glucose tolerance . This study open-label single arm study . Funding Source - FDA OOPD</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Quercetin</mesh_term>
	<criteria>Diagnosis FA proven DEB test Able take enteral medication All age group , include adult Patients morphological evidence myelodysplasia leukemia Renal failure require dialysis Total bilirubin &gt; 3 mg/dl and/or SGPT &gt; 200 time enrollment Patients pregnant breastfeed risk pregnancy unable use acceptable method birth control length study Patients receive cyclosporine digoxin therapy unable discontinue either treatment due medical reason</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Fanconi Anemia</keyword>
	<keyword>FA</keyword>
	<keyword>Quercetin</keyword>
</DOC>